News Releases Joni Henderson 3/19/26 Joni Henderson 3/19/26 C2N HIGHLIGHTS FIRST USE OF ITS eMTBR-TAU243 PLASMA ASSAY IN EVOKE/EVOKE+ PHASE 3 DATASET FOR PREDICTION OF COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH EARLY SYMPTOMATIC AD Read More Joni Henderson 3/11/26 Joni Henderson 3/11/26 C2N Diagnostics Enters South Korean Market Through Partnership withBeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests toHelp Doctors Diagnose Alzheimer’s Disease Read More Joni Henderson 11/24/25 Joni Henderson 11/24/25 C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests toHelp Diagnose Alzheimer’s Disease Read More Joni Henderson 11/13/25 Joni Henderson 11/13/25 C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization Read More Joni Henderson 10/1/25 Joni Henderson 10/1/25 C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test Read More Joni Henderson 9/25/25 Joni Henderson 9/25/25 New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients Read More Joni Henderson 9/3/25 Joni Henderson 9/3/25 Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease Read More Joni Henderson 8/25/25 Joni Henderson 8/25/25 C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older Read More Joni Henderson 8/7/25 Joni Henderson 8/7/25 C2N Announces Major Global Expansion, Adds Six New International Partners Read More Joni Henderson 7/15/25 Joni Henderson 7/15/25 C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias Read More Joni Henderson 3/12/25 Joni Henderson 3/12/25 Samsung Invests in C2N Diagnostics Read More Joni Henderson 2/24/25 Joni Henderson 2/24/25 C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom Read More Joni Henderson 1/31/25 Joni Henderson 1/31/25 Study Highlights How C2N’s PrecivityAD2™ Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease Read More Joni Henderson 1/28/25 Joni Henderson 1/28/25 First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology Read More Joni Henderson 1/15/25 Joni Henderson 1/15/25 C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease Read More Joni Henderson 9/30/24 Joni Henderson 9/30/24 C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease Read More Joni Henderson 9/25/24 Joni Henderson 9/25/24 C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide Read More Joni Henderson 7/28/24 Joni Henderson 7/28/24 JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care Read More Joni Henderson 7/2/24 Joni Henderson 7/2/24 C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology Read More Joni Henderson 6/26/24 Joni Henderson 6/26/24 C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories Read More Older Posts
Joni Henderson 3/19/26 Joni Henderson 3/19/26 C2N HIGHLIGHTS FIRST USE OF ITS eMTBR-TAU243 PLASMA ASSAY IN EVOKE/EVOKE+ PHASE 3 DATASET FOR PREDICTION OF COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH EARLY SYMPTOMATIC AD Read More
Joni Henderson 3/11/26 Joni Henderson 3/11/26 C2N Diagnostics Enters South Korean Market Through Partnership withBeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests toHelp Doctors Diagnose Alzheimer’s Disease Read More
Joni Henderson 11/24/25 Joni Henderson 11/24/25 C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests toHelp Diagnose Alzheimer’s Disease Read More
Joni Henderson 11/13/25 Joni Henderson 11/13/25 C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization Read More
Joni Henderson 10/1/25 Joni Henderson 10/1/25 C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test Read More
Joni Henderson 9/25/25 Joni Henderson 9/25/25 New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients Read More
Joni Henderson 9/3/25 Joni Henderson 9/3/25 Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease Read More
Joni Henderson 8/25/25 Joni Henderson 8/25/25 C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older Read More
Joni Henderson 8/7/25 Joni Henderson 8/7/25 C2N Announces Major Global Expansion, Adds Six New International Partners Read More
Joni Henderson 7/15/25 Joni Henderson 7/15/25 C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias Read More
Joni Henderson 2/24/25 Joni Henderson 2/24/25 C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom Read More
Joni Henderson 1/31/25 Joni Henderson 1/31/25 Study Highlights How C2N’s PrecivityAD2™ Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease Read More
Joni Henderson 1/28/25 Joni Henderson 1/28/25 First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology Read More
Joni Henderson 1/15/25 Joni Henderson 1/15/25 C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease Read More
Joni Henderson 9/30/24 Joni Henderson 9/30/24 C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease Read More
Joni Henderson 9/25/24 Joni Henderson 9/25/24 C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide Read More
Joni Henderson 7/28/24 Joni Henderson 7/28/24 JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care Read More
Joni Henderson 7/2/24 Joni Henderson 7/2/24 C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology Read More
Joni Henderson 6/26/24 Joni Henderson 6/26/24 C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories Read More
